Icure Pharmaceutical Incorporation reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 1,794.49 million compared to KRW 172.76 million a year ago. Net loss was KRW 7,147.4 million compared to KRW 6,873.81 million a year ago.

Basic loss per share from continuing operations was KRW 190 compared to KRW 303.3333 a year ago. Diluted loss per share from continuing operations was KRW 190 compared to KRW 303.3333 a year ago. Basic loss per share was KRW 190 compared to KRW 364 a year ago.